Shanghai UniXell Biotechnology Co., Ltd

UniXeII Biotechnology, a company in the field of human PSC derived cell therapy for neurological diseases, was founded in 2021. It has developed four highly innovative and integrated technology: Reprogramming technology, Stem cell differentiation, SISBAR lineage tracing technology, High-precision gene editing. These technological advantages enable UniXeII to manufacture cell products of high purity and batch consistency, advancing toward the ultimate clinical goals of efficacy and safety. DA001, a midbrain dopaminergic progenitor cells product for Parkinson's disease, is the first pipeline and now rapidly advancing into clinical trial.